MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
about
Interventions in the management of serum lipids for preventing stroke recurrenceAntioxidant supplements for preventing gastrointestinal cancersAntioxidant supplements for prevention of mortality in healthy participants and patients with various diseasesAntioxidant supplements for preventing gastrointestinal cancersThe effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trialPosition statement on human agingDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewSigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials.Is hypercholesterolemia a risk factor and should it be treated in the elderly?Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review.Experimental approaches and drugs in development for the treatment of dementia.Lessons learned from statin trials.Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patienInterventions in the management of serum lipids for preventing stroke recurrence.The reno-protective role of AT(1)-receptor blockers.Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.Hypolipemic agents for stroke prevention.Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS studyImpact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection StudyRosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E.Targeted versus global approaches to the management of hypercholesterolaemia.Glomerular filtration rate and blood pressure are unchanged by increased sodium intake in atorvastatin-treated healthy men.
P2860
Q24240060-58CD3032-09E8-40AE-AE9D-2EABCA415C7AQ24242191-E99AAD90-F3C6-43DD-B756-F02A17A6ABC2Q24242944-F94D9745-BEDD-457C-9A12-71ED24EC1605Q24245704-51B2541A-C615-4F7F-B3DC-C6499EB90CDEQ24793837-CEBEA1F5-D0E5-4178-AE54-EE872E38E66FQ24794251-83879B72-F4FD-4F94-B32B-DE801E8112B3Q28195696-9D674661-8AE4-4273-9C63-B2ED5C60D60FQ28216232-BFA44DD4-A185-419E-B26D-EA3BEC04F66EQ28474985-EF6BF50C-5312-4C65-A24A-1EBA379F5DF0Q34041102-58C15710-D915-458E-93DE-AEDA2FC06B36Q34077942-FE9F4E2D-C6E1-42E8-BDEA-D371FD893686Q34126037-0D57F111-FC69-495A-AB00-614551AD1CECQ34204320-D7503A8B-B0C5-406D-86F5-C70DFFFC8E30Q34219867-627F585F-DB62-492D-A50E-31F01CE8A08FQ34389584-16CA6F6E-DCB6-4EE1-B9AA-79E6559EE7F4Q34506856-CE1ABD86-A66B-441A-87E0-9E96608AA312Q34757974-2D154394-7FCF-4082-816C-489B44C4D6D1Q34761197-943B7607-32C1-4EE2-836A-858DF6A55A51Q34773911-EE0A5227-8E37-4DD0-A05B-BC988C23141AQ35008533-D8EA9780-7C86-4B54-913F-C306CD0510ACQ35015565-5BC647F4-7E3F-47F0-A083-B0FD970D2314Q35964012-9A0F0F2B-8952-4503-958A-D3D8B3EC0F3FQ36730132-559F59CE-8C0E-4195-BE41-89F65E349A35Q36752063-F47C63CC-00DF-4D25-B6B5-D152E10D8902Q37020195-7860AC66-6DAC-48C4-9FDE-D2EFBCFCBFA5Q37177038-298A25D5-86D0-4D08-A5B1-FD044B362DEEQ44053804-6E03E0C6-EA5D-4C24-8636-9D0F2B162308Q44983323-93FE8E04-9AF7-4B12-B155-FBBD5C35D8C4Q46218094-2EF84F5D-4938-4210-9A0A-4EBD6F449202
P2860
MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
description
im Mai 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 1999
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 1999
@uk
name
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@en
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@nl
type
label
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@en
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@nl
prefLabel
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@en
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@nl
P356
P1476
MRC/BHF Heart Protection Study ...... safety and efficacy experience
@en
P304
P356
10.1053/EUHJ.1998.1350
P577
1999-05-01T00:00:00Z